Alliance for Regenerative Medicine Releases 2015 Annual Data Report, Highlighting Sector Trends and Metrics

– February 17, 2016

WASHINGTON, D.C., February 18, 2016 – The Alliance for Regenerative Medicine (ARM) today announced the release of its annual data report, offering an in-depth look at sector trends and metrics in 2015.

Using information provided by ARM’s data partner Informa, the annual data report details industry-specific statistics compiled from more than 670 leading gene therapy, cell therapy and other regenerative medicine companies worldwide, including total financings, partnering and dealmaking, clinical trial information, key data events and ARM’s strategic priorities for 2016.

The 2015 annual report includes several sections featuring ARM member company perspectives, highlighting important focus areas for the sector:

  • The partnering and dealmaking environment, with commentary from Cellular Dynamics International (a FUJIFILM company), Novartis and Voyager Therapeutics, Inc.
  • Europe’s regenerative medicine and advanced therapy sector, with commentary from Cellectis, Celyad and Bone Therapeutics.
  • CAR-T and adoptive T-cell therapies, with commentary from Juno Therapeutics and Novartis.
  • Gene editing technologies, with commentary from Cellectis, Precision BioSciences and Sangamo BioSciences.

“This past year was a watershed in terms of the amount of money raised by gene and cell therapy companies, as well as the the vote of confidence in the sector from large pharma and large-cap biotech companies, visible in the record number of investments and high-value corporate partnerships,” said Morrie Ruffin, ARM’s managing director. “We recognize, however, that the financing environment has changed significantly since Q3 2015 and the greatest need now is to continue to show steady, meaningful clinical progress in areas of significant unmet medical need.”

Highlighted findings from the 2015 annual report include:

  • Globally, companies active in gene and cellular therapies and other regenerative medicines raised more than $10.8 billion in 2015, up 106 percent when compared to 2014. The report also includes data broken out by technology and financing type.
  • There were 631 clinical trials underway worldwide at the close of 2015. The report includes figures on clinical trials by phase and indication.
  • Areas of strategic focus in 2016, including reimbursement policies; ARM’s Standards Coordinating Body initiative; international regulatory harmonization; manufacturing and scalability challenges; capital formation; patient advocacy and more.

In addition to its annual data report, ARM provides quarterly data updates, released after the close of each quarter, tracking sector performance, key financial, clinical trial information and data events.

The report is available online. For more information, please visit or contact Lyndsey Scull at

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 230 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit